Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 16.2% in April

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 2,330,000 shares, a drop of 16.2% from the March 31st total of 2,780,000 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily volume of 505,600 shares, the short-interest ratio is presently 4.6 days.

ACRS has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aclaris Therapeutics in a research note on Friday, February 25th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, StockNews.com initiated coverage on Aclaris Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Buy” and an average price target of $30.50.

In related news, CFO Frank Ruffo sold 12,823 shares of the company’s stock in a transaction that occurred on Thursday, March 10th. The shares were sold at an average price of $15.55, for a total value of $199,397.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Neal Walker sold 20,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $15.18, for a total transaction of $303,600.00. Following the sale, the chief executive officer now owns 1,245,763 shares of the company’s stock, valued at $18,910,682.34. The disclosure for this sale can be found here. Over the last three months, insiders sold 171,674 shares of company stock valued at $2,699,797. Insiders own 8.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd bought a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $26,000. Macquarie Group Ltd. bought a new position in Aclaris Therapeutics in the third quarter worth $28,000. UBS Group AG lifted its position in Aclaris Therapeutics by 130.0% during the third quarter. UBS Group AG now owns 1,650 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 7,151 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth about $43,000. Finally, Royal Bank of Canada increased its stake in shares of Aclaris Therapeutics by 73.0% in the 3rd quarter. Royal Bank of Canada now owns 5,146 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 2,172 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

ACRS opened at $13.07 on Wednesday. Aclaris Therapeutics has a one year low of $9.26 and a one year high of $24.94. The business has a 50 day simple moving average of $15.81 and a two-hundred day simple moving average of $14.31.

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). The business had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $1.80 million. Aclaris Therapeutics had a negative return on equity of 47.82% and a negative net margin of 1,343.96%. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities research analysts forecast that Aclaris Therapeutics will post -1.84 EPS for the current fiscal year.

About Aclaris Therapeutics (Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Stories

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.